Axovant Gene Therapies (NASDAQ:AXGT) Posts Quarterly Earnings Results, Beats Estimates By $1.25 EPS
Axovant Gene Therapies (NASDAQ:AXGT) issued its quarterly earnings results on Tuesday. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($1.70) by $1.25, Fidelity Earnings reports.
NASDAQ:AXGT traded up $0.06 during mid-day trading on Wednesday, hitting $4.00. The stock had a trading volume of 14,202 shares, compared to its average volume of 293,674. Axovant Gene Therapies has a twelve month low of $3.81 and a twelve month high of $39.52. The company has a debt-to-equity ratio of 1.24, a quick ratio of 2.02 and a current ratio of 2.02. The company has a market capitalization of $89.75 million, a P/E ratio of -0.24 and a beta of 1.39.
An institutional investor recently bought a new position in Axovant Gene Therapies stock. Morgan Stanley acquired a new position in shares of Axovant Gene Therapies Ltd (NASDAQ:AXGT) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 219,097 shares of the company’s stock, valued at approximately $291,000. Morgan Stanley owned 0.96% of Axovant Gene Therapies at the end of the most recent reporting period.
Axovant Gene Therapies Company Profile
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.
Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.